Meta-analysis of the relationship between interleukin-6 levels and the prognosis and severity of acute coronary syndrome
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinics |
Texto Completo: | https://www.revistas.usp.br/clinics/article/view/213036 |
Resumo: | This study aimed to explore the relationship between plasma interleukin 6 (IL-6) levels, adverse cardiovascular events, and the severity of acute coronary syndrome (ACS). A literature review was performed of studies regarding IL-6 and ACS extracted from databases including EMBASE, Cqvip, MEDLINE, Web of Knowledge, PubMed, Cochrane Library, China National Knowledge Infrastructure, and Wanfang data. The Newcastle-Ottawa scale (NOS) was used to evaluate the quality of the literature. The literature was screened, its quality was evaluated, and relevant data were extracted for performing meta-analysis using RevMan software (version 5.3). A total of 524 studies were included in the initial survey. After several rounds of screening and analysis, six studies met the inclusion criteria and underwent meta-analysis using a fixed-effect model. Patients were divided into non-severe and severe groups based on the concentration of high-sensitivity C-reactive protein. Meta-analysis of the relationship between IL-6 and the severity of ACS showed that the plasma IL-6 level of patients in the severe group was significantly higher than that of patients in the non-severe group (p<0.00001). Additionally, patients with experience of major adverse cardiovascular events had significantly higher plasma IL-6 levels than did patients without experience of such events (p<0.00001). In summary, patients with ACS and high IL-6 levels tended to be in a critical condition, with a higher risk of adverse cardiovascular events and worse prognosis. Thus, IL-6 levels could indicate whether patients with ACS may have adverse cardiovascular events and determine the severity of ACS. |
id |
USP-19_0659f173dda941088d1c80b69e8bee7f |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/213036 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
Meta-analysis of the relationship between interleukin-6 levels and the prognosis and severity of acute coronary syndromeAcute Coronary SyndromeInterleukin 6Major Adverse Cardiovascular EventMeta-AnalysisThis study aimed to explore the relationship between plasma interleukin 6 (IL-6) levels, adverse cardiovascular events, and the severity of acute coronary syndrome (ACS). A literature review was performed of studies regarding IL-6 and ACS extracted from databases including EMBASE, Cqvip, MEDLINE, Web of Knowledge, PubMed, Cochrane Library, China National Knowledge Infrastructure, and Wanfang data. The Newcastle-Ottawa scale (NOS) was used to evaluate the quality of the literature. The literature was screened, its quality was evaluated, and relevant data were extracted for performing meta-analysis using RevMan software (version 5.3). A total of 524 studies were included in the initial survey. After several rounds of screening and analysis, six studies met the inclusion criteria and underwent meta-analysis using a fixed-effect model. Patients were divided into non-severe and severe groups based on the concentration of high-sensitivity C-reactive protein. Meta-analysis of the relationship between IL-6 and the severity of ACS showed that the plasma IL-6 level of patients in the severe group was significantly higher than that of patients in the non-severe group (p<0.00001). Additionally, patients with experience of major adverse cardiovascular events had significantly higher plasma IL-6 levels than did patients without experience of such events (p<0.00001). In summary, patients with ACS and high IL-6 levels tended to be in a critical condition, with a higher risk of adverse cardiovascular events and worse prognosis. Thus, IL-6 levels could indicate whether patients with ACS may have adverse cardiovascular events and determine the severity of ACS.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2021-07-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/21303610.6061/clinics/2021/e2690Clinics; Vol. 76 (2021); e2690Clinics; v. 76 (2021); e2690Clinics; Vol. 76 (2021); e26901980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/213036/195042Copyright (c) 2023 Clinicsinfo:eu-repo/semantics/openAccessYang, ChongzheDeng, ZhiyongLi, JieRen, ZhileiLiu, Feng2023-07-06T13:04:10Zoai:revistas.usp.br:article/213036Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2023-07-06T13:04:10Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Meta-analysis of the relationship between interleukin-6 levels and the prognosis and severity of acute coronary syndrome |
title |
Meta-analysis of the relationship between interleukin-6 levels and the prognosis and severity of acute coronary syndrome |
spellingShingle |
Meta-analysis of the relationship between interleukin-6 levels and the prognosis and severity of acute coronary syndrome Yang, Chongzhe Acute Coronary Syndrome Interleukin 6 Major Adverse Cardiovascular Event Meta-Analysis |
title_short |
Meta-analysis of the relationship between interleukin-6 levels and the prognosis and severity of acute coronary syndrome |
title_full |
Meta-analysis of the relationship between interleukin-6 levels and the prognosis and severity of acute coronary syndrome |
title_fullStr |
Meta-analysis of the relationship between interleukin-6 levels and the prognosis and severity of acute coronary syndrome |
title_full_unstemmed |
Meta-analysis of the relationship between interleukin-6 levels and the prognosis and severity of acute coronary syndrome |
title_sort |
Meta-analysis of the relationship between interleukin-6 levels and the prognosis and severity of acute coronary syndrome |
author |
Yang, Chongzhe |
author_facet |
Yang, Chongzhe Deng, Zhiyong Li, Jie Ren, Zhilei Liu, Feng |
author_role |
author |
author2 |
Deng, Zhiyong Li, Jie Ren, Zhilei Liu, Feng |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Yang, Chongzhe Deng, Zhiyong Li, Jie Ren, Zhilei Liu, Feng |
dc.subject.por.fl_str_mv |
Acute Coronary Syndrome Interleukin 6 Major Adverse Cardiovascular Event Meta-Analysis |
topic |
Acute Coronary Syndrome Interleukin 6 Major Adverse Cardiovascular Event Meta-Analysis |
description |
This study aimed to explore the relationship between plasma interleukin 6 (IL-6) levels, adverse cardiovascular events, and the severity of acute coronary syndrome (ACS). A literature review was performed of studies regarding IL-6 and ACS extracted from databases including EMBASE, Cqvip, MEDLINE, Web of Knowledge, PubMed, Cochrane Library, China National Knowledge Infrastructure, and Wanfang data. The Newcastle-Ottawa scale (NOS) was used to evaluate the quality of the literature. The literature was screened, its quality was evaluated, and relevant data were extracted for performing meta-analysis using RevMan software (version 5.3). A total of 524 studies were included in the initial survey. After several rounds of screening and analysis, six studies met the inclusion criteria and underwent meta-analysis using a fixed-effect model. Patients were divided into non-severe and severe groups based on the concentration of high-sensitivity C-reactive protein. Meta-analysis of the relationship between IL-6 and the severity of ACS showed that the plasma IL-6 level of patients in the severe group was significantly higher than that of patients in the non-severe group (p<0.00001). Additionally, patients with experience of major adverse cardiovascular events had significantly higher plasma IL-6 levels than did patients without experience of such events (p<0.00001). In summary, patients with ACS and high IL-6 levels tended to be in a critical condition, with a higher risk of adverse cardiovascular events and worse prognosis. Thus, IL-6 levels could indicate whether patients with ACS may have adverse cardiovascular events and determine the severity of ACS. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-07-05 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/213036 10.6061/clinics/2021/e2690 |
url |
https://www.revistas.usp.br/clinics/article/view/213036 |
identifier_str_mv |
10.6061/clinics/2021/e2690 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/213036/195042 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2023 Clinics info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2023 Clinics |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; Vol. 76 (2021); e2690 Clinics; v. 76 (2021); e2690 Clinics; Vol. 76 (2021); e2690 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1800222766244298752 |